NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer

Early Phase 1

Terminated

Conditions: Uterine Cervical Neoplasms

Interventions: Biological: E7 T-Cell Receptor (TCR)

First Posted Date: 2020-07-20

Last Posted Date: 2021-12-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT04476251

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mobile Sensor Technologies to Assess General Symptomology of People With Cancer

Completed

Conditions: Neoplasms
Colon Cancer
Lung Cancer
Prostate Cancer
Solid Tumors

First Posted Date: 2020-07-10

Last Posted Date: 2025-03-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT04465214

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Phase 1

Active, not recruiting

Conditions: Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Distal Esophagus Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8

Interventions: Drug: Adavosertib
Radiation: Radiation Therapy

First Posted Date: 2020-07-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT04460937

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 4 locations

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Phase 2

Active, not recruiting

Conditions: Central Chondrosarcoma, Grade 2
Central Chondrosarcoma, Grade 3
Dedifferentiated Chondrosarcoma
Metastatic Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma
Metastatic Clear Cell Sarcoma of Soft Tissue

Interventions: Drug: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography

First Posted Date: 2020-07-07

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT04458922

Locations: 🇺🇸
Siteman Cancer Center-South County, Saint Louis, Missouri, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 12 locations

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3

Terminated

Conditions: Stage IVB Nasopharyngeal Carcinoma AJCC v8
Metastatic Nasopharyngeal Undifferentiated Carcinoma
Nasopharyngeal Nonkeratinizing Carcinoma
Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Recurrent Nasopharyngeal Undifferentiated Carcinoma
Metastatic Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8
Stage IVA Nasopharyngeal Carcinoma AJCC v8
Metastatic Nasopharyngeal Nonkeratinizing Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2020-07-07

Last Posted Date: 2024-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT04458909

Locations: 🇺🇸
Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States
🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States

and more 322 locations

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Phase 2

Recruiting

Conditions: Neoplasms

Interventions: Drug: Nilotinib and Paclitaxel

First Posted Date: 2020-06-29

Last Posted Date: 2025-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 82

Registration Number: NCT04449549

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1

Active, not recruiting

Conditions: Cutaneous T-Cell Lymphoma
Mature T-cell Malignancies
Peripheral T-Cell Lymphoma
Relapsed/ Refractory T-cell Malignancies

Interventions: Drug: Romidepsin
Drug: Lenalidomide
Drug: CC-486 (5-azacitidine)
Drug: Dexamethasone

First Posted Date: 2020-06-25

Last Posted Date: 2024-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT04447027

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Terminated

Conditions: Adrenocortical Cancer
Adrenocortical Carcinoma

First Posted Date: 2020-06-25

Last Posted Date: 2023-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT04447014

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Phase 3

Active, not recruiting

Conditions: Anal Basaloid Carcinoma
Anal Canal Cloacogenic Carcinoma
Metastatic Anal Squamous Cell Carcinoma
Recurrent Anal Squamous Cell Carcinoma
Stage III Anal Cancer AJCC v8
Stage IV Anal Cancer AJCC v8
Unresectable Anal Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Biological: Nivolumab

First Posted Date: 2020-06-24

Last Posted Date: 2025-03-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 205

Registration Number: NCT04444921

Locations: 🇺🇸
Walter Knox Memorial Hospital, Emmett, Idaho, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 579 locations

Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain

Completed

Conditions: Solid Tumors
Neoplasms
Cancer

First Posted Date: 2020-06-22

Last Posted Date: 2025-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 83

Registration Number: NCT04442425

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy